TherapeuticsMD Inc Total Liabilities
TherapeuticsMD Inc total liabilities. Based on the latest financial reports, TherapeuticsMD Inc (TXMD) has total liabilities worth $10.78 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check TXMD cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of TherapeuticsMD Inc (1994–2025)
Total liabilities of TherapeuticsMD Inc from 1994 to 2025. This chart illustrates how TherapeuticsMD Inc's total liabilities have evolved over time, based on quarterly financial data.
TherapeuticsMD Inc Competitors by Total Liabilities
The table below lists competitors of TherapeuticsMD Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bangsaphan Barmill Public Company Limited
BK:BSBM
|
Thailand | ฿20.36 Million |
|
Duckshin Housing Co. Ltd
KQ:090410
|
Korea | ₩94.73 Billion |
|
Cocrystal Pharma Inc
NASDAQ:COCP
|
USA | $3.60 Million |
|
Zuleika Gold Ltd
AU:ZAG
|
Australia | AU$2.06 Million |
|
Food and Drinks Public Company Limited
BK:F&D
|
Thailand | ฿519.07 Million |
|
Kintech Electronics Co Ltd
TWO:6210
|
Taiwan | NT$124.90 Million |
|
Sebang Co Ltd
KO:004365
|
Korea | ₩308.61 Billion |
|
Alla Public Company Limited
BK:ALLA
|
Thailand | ฿212.07 Million |
Liability Composition Analysis (1994–2025)
This chart breaks down TherapeuticsMD Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see TXMD total assets.
Liquidity & Leverage Metrics
TherapeuticsMD Inc Total Liabilities Ratios Explained
TherapeuticsMD Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TherapeuticsMD Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TherapeuticsMD Inc (1994–2025)
The table below shows the annual total liabilities of TherapeuticsMD Inc from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.78 Million | -5.87% |
| 2024-12-31 | $11.45 Million | -18.33% |
| 2023-12-31 | $14.02 Million | -74.65% |
| 2022-12-31 | $55.31 Million | -78.98% |
| 2021-12-31 | $263.09 Million | -13.91% |
| 2020-12-31 | $305.61 Million | +19.01% |
| 2019-12-31 | $256.78 Million | +124.34% |
| 2018-12-31 | $114.46 Million | +759.23% |
| 2017-12-31 | $13.32 Million | -11.09% |
| 2016-12-31 | $14.98 Million | +40.47% |
| 2015-12-31 | $10.67 Million | -0.23% |
| 2014-12-31 | $10.69 Million | +46.08% |
| 2013-12-31 | $7.32 Million | +0.92% |
| 2012-12-31 | $7.25 Million | +130.16% |
| 2011-12-31 | $3.15 Million | +129.14% |
| 2010-12-31 | $1.37 Million | +18.45% |
| 2009-12-31 | $1.16 Million | +3149.59% |
| 2008-12-31 | $35.72K | -54.10% |
| 2007-12-31 | $77.83K | -56.72% |
| 2006-12-31 | $179.83K | -63.54% |
| 2005-12-31 | $493.18K | +1228.79% |
| 2004-12-31 | $37.12K | +15.59% |
| 2003-12-31 | $32.11K | +91.08% |
| 2002-12-31 | $16.80K | -27.06% |
| 2001-12-31 | $23.04K | +42.16% |
| 2000-12-31 | $16.21K | -9.00% |
| 1999-12-31 | $17.81K | -64.89% |
| 1998-12-31 | $50.72K | +626.39% |
| 1997-12-31 | $6.98K | +44.76% |
| 1996-12-31 | $4.82K | -92.52% |
| 1995-12-31 | $64.49K | +462.21% |
| 1994-12-31 | $11.47K | -- |
About TherapeuticsMD Inc
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vag… Read more